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Background: Adherence to treatment is often reported to be low in children with cystic fibrosis. Adherence in
cystic fibrosis is an important research area and more research is needed to better understand family barriers to
adherence in order for clinicians to provide appropriate intervention. The aim of this study was to evaluate adherence to
enzyme supplements, vitamins and chest physiotherapy in children with cystic fibrosis and to determine if any modifiable
risk factors are associated with adherence.
Methods: A sample of 100 children (≤18 years) with cystic fibrosis (44 male; median [range] 10.1 [0.2-18.6]
years) and their parents were recruited to the study from the Northern Ireland Paediatric Cystic Fibrosis Centre.
Adherence to enzyme supplements, vitamins and chest physiotherapy was assessed using a multi-method approach
including; Medication Adherence Report Scale, pharmacy prescription refill data and general practitioner prescription issue
data. Beliefs about treatments were assessed using refined versions of the Beliefs about Medicines Questionnaire-specific.
Parental depressive symptoms were assessed using the Center for Epidemiologic Studies Depression Scale.
Results: Using the multi-method approach 72% of children were classified as low-adherers to enzyme supplements,
59% low-adherers to vitamins and 49% low-adherers to chest physiotherapy. Variations in adherence were observed
between measurement methods, treatments and respondents. Parental necessity beliefs and child age were significant
independent predictors of child adherence to enzyme supplements and chest physiotherapy, but parental depressive
symptoms were not found to be predictive of adherence.
Conclusions: Child age and parental beliefs about treatments should be taken into account by clinicians when
addressing adherence at routine clinic appointments. Low adherence is more likely to occur in older children,
whereas, better adherence to cystic fibrosis therapies is more likely in children whose parents strongly believe the
treatments are necessary. The necessity of treatments should be reinforced regularly to both parents and children.
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Adherence to treatment (or carrying out agreed health-
care recommendations) is approximately 50% in most
chronic diseases and has been described as a “worldwide
problem of striking magnitude” [1]. Cystic fibrosis is a
complex, multi-system disease which presents both
affected children and their parents with significant
challenges regarding treatment management. Often the
most effective treatments are complex and time con-
suming to administer [2]. Although children may be
prescribed the most appropriate treatment and given
appropriate advice, adherence to treatment recommen-
dations in children with cystic fibrosis is reported to be
below 50% [3]. Poor adherence has been linked to a
decline in health outcomes such as pulmonary exacer-
bations, decline in baseline lung function and risk of
hospitalisation [4,5]. Adherence to therapy is therefore
essential to prevent worsening of the disease. Little is
known about the extent of adherence to treatment in
children with cystic fibrosis in the UK or indeed the
factors affecting adherence in this population.
A factor that has been shown to account for a signifi-
cant amount of the variance in adherence to treatment
in several chronic diseases is beliefs about treatment
[6,7]. It has been proposed that patients carry out an
internal ‘cost-benefit’ analysis with regards to taking
medicines, weighing up their perceived necessity and
their concerns about the treatment [8]. High self-reported
adherence to medications for chronic conditions in adults
has been associated with high necessity beliefs and low
concern beliefs using a necessity-concerns framework [6].
Equally, low necessity beliefs and high concerns about the
potential harm of medication have been correlated with
low adherence [6,9]. These treatment beliefs in relation to
adherence have been underexplored in cystic fibrosis. One
small study in adolescents with cystic fibrosis investigated
beliefs about antibiotics, enzyme supplements and chest
physiotherapy and found that doubts about necessity of
antibiotics and chest physiotherapy were predictive of
adherence [10]. Additionally, interviews with adolescents
with cystic fibrosis and their parents identified that recog-
nising the importance of therapies was a facilitator of
adherence [11]. It is particularly pertinent to consider
parental beliefs when considering chronic childhood
diseases, where parents are responsible for administering
or supervising their child’s therapy. Improved adherence
to asthma treatment in children has been reported
when their parents exhibit increased necessity-concern
differentials (i.e. high necessity scores and low concern
scores) [12].
Parental depression has previously been linked to
poor adherence to treatment in children with asthma
[13]. There is a paucity of data, on whether parental
depressive symptoms influence adherence to treatmentin children with cystic fibrosis in the UK. Recently there
has been a focus in determining the prevalence of
depressive symptoms present in children with cystic
fibrosis and their caregivers through The International
Depression/anxiety Epidemiology Study-CF (TIDES-CF)
(www.tides-cf.org/) [14]. A significant association between
depression present in mothers and an increase in child
non-adherence to pancreatic enzyme supplements was
reported in the US [15]. Similarly, Smith and Wood re-
ported an association between parental depression and
low adherence to chest physiotherapy in the US [16]. In
contrast, a subsequent paper by Smith and colleagues, in
2010, reported that maternal depressive symptoms were
positively related to adolescent adherence to chest physio-
therapy [17]. This seemingly counter-intuitive finding was
perceived to be due to either children being forced to
become autonomous with respect to treatment or
mothers putting excessive effort into airway clearance
adherence and depressive symptoms manifesting in a
subsequent ‘burn out’. Finally, a study conducted in
Australia has shown that poor caregiver mental health
was predictive of child non-adherence to chest physio-
therapy [18].
Although studies have investigated cystic fibrosis treat-
ment adherence in adults in the UK and both children
and adults in the United States, there has been a lack of
published research to date that has addressed adherence
to treatment in children with cystic fibrosis in the UK.
There are significant differences in healthcare provision
and culture between the UK and USA; it therefore
would be inaccurate to assume that factors relevant to
adherence in the USA are the same as those affecting
children with cystic fibrosis in the UK. Furthermore, no
study has yet investigated parent-reported beliefs about
treatments. The aim of the present study was to examine
adherence to treatment in children with cystic fibrosis
and determine if any modifiable risk factors, specifically
beliefs about treatment and parental depressive symp-
toms, are associated with adherence. It was hypothesized
that stronger necessity beliefs would result in increased
treatment adherence whereas, stronger concern beliefs
would result in lower treatment adherence. Additionally
it was hypothesized that parental depressive symptoms
would be associated with low adherence to treatment.
Methods
Participants
Favourable ethical opinion was granted by the Office for
Research Ethics Northern Ireland (10/NIR02/42) and
research governance approval was obtained from the
Belfast Health and Social Care Trust (10095-AR-FC). A
convenience sample of 100 children and their parents
were consecutively recruited at the outpatient clinic of
the Northern Ireland Paediatric Cystic Fibrosis Centre.
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the child had a consultant confirmed diagnosis of cystic
fibrosis and was aged ≤18 years. Parents (and children)
were not approached if the child had experienced a recent
death in the family, if the child (≥6 years) was deemed by
their doctor as not capable to provide assent or if the child
was not accompanied to the clinic by a parent or guardian.
Written consent was obtained from parents and assent
obtained from children (≥6 years) after full explanation of
the study. Throughout this paper the term child/children
refers to children and young people 0-18 years old and the
term parent describes the parents and/or guardians of
these children.
Children were only included in the study once in-
formed consent was obtained from their parent and
assent was obtained as detailed above. Upon enrolment,
baseline data were collected via interview and review of
medical notes. Details recorded included sociodemographic
data, healthcare provider details, medical history, current
medication, additional therapies, clinical outcome data
(weight, height, pulmonary function, Shwachman radio-
logical score, bacterial colonisation status) and number of
hospitalisations in the previous year. Following baseline
data collection a series of questionnaires were administered
to children and their parents by a research nurse or research
pharmacist. The questionnaires were completed inde-
pendently by parent and child at a time convenient to the
running of the clinic.
Measures
Composite adherence measurement
When measuring adherence it is recommended that a
multi-method approach is employed, including both a
self-report instrument and an objective measurement
tool [1,3]. In the present study adherence levels to
enzyme supplements, vitamins and chest physiotherapy
were assessed using (a) scores from parent and/or child
Medication Adherence Report Scale [19], (b) Patient
Medication Records from each patient’s community
pharmacist and (c) prescription records from the pa-
tient’s general practitioner (GP), as appropriate. A com-
posite adherence measurement approach was used so
that a child was designated as a low-adherer if they
scored less than 80% in any one of the methods de-
scribed. This dichotomous approach was employed to
triangulate up to four different measurement methods
of adherence. The threshold of 80% was chosen as this is
the generally accepted lower limit of adherence adopted in
a range of research articles after which point adherence
may have a direct impact on patient outcomes [20].
(a)Medication Adherence Report Scale (MARS)
Measuring self-reported non-adherence as opposed
to self-reported adherence has been shown tocorrelate more closely to objective adherence measures
such as pill counts [21]. The MARS questionnaire was
used to measure the frequency of non-adherence to
enzyme supplements, vitamins and chest physiotherapy
with separate versions administered to parents and
children (≥11 years). Each question was scored on
a 1-5 Likert scale (always-never). Answers to each
question were summed and transformed to range
from 0-100, with higher scores indicating higher
levels of self-reported adherence. If a parent stated
that they were not responsible for treatment
supervision/administration the parent MARS was
not completed.
Previously, when the MARS was administered to a
sample of adolescents with cystic fibrosis to measure
adherence to enzyme supplements, the internal
consistency was low (α = 0.51) [10]. In an attempt to
address this previously reported poor internal
consistency with regards to enzyme supplements,
one item was added and successfully piloted with 10
parents and children (≥11 years); ‘I/My child forgets
to take them with snacks’, no further amendments
were requested.
The internal reliability, as measured by Cronbach’s
alpha, for the MARS questionnaire for children was
above 0.7 for each treatment. The internal reliability
for the MARS parent scales were above 0.7 for
vitamins and chest physiotherapy, however, the parent
scale for enzyme supplements was low (α = 0.48).
Principal Component Analysis (PCA) revealed that
question 2, “I alter the dose”, from the parent MARS
questionnaire for enzyme supplements loaded onto a
separate component and had a low correlation with
the other remaining questions on the scale. After
removal of Question 2, the internal reliability
improved (α = 0.60) and PCA indicated that the
remaining items primarily loaded onto one
component i.e. non-adherence. All analyses were
therefore conducted after the removal of question 2
on the parent MARS for enzyme supplements.
(b)Community pharmacy Patient Medication
Records (PMRs)
Children were classified as low-adherers to enzyme
supplements or vitamins if their community pharmacy
records illustrated that they were dispensed less than
80% of the prescribed amounts during the previous
12months. This was calculated using theMedication
Refill Adherence (MRA)method recommended by
Hess et al. [22] For patients who had an inpatient stay
in hospital, during the 12months prior to enrolment in
the study, the length of stay was deducted from the total
number of days evaluated to account for medication
provided while in hospital [4]. Therefore, the revised
calculation was:
MRA ¼ Total days supply during study period
Total number of days evaluated – Days admitted to hospital
 100%
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Similarly, patients were classified as low-adherers if
the prescription issue records for enzyme supplements
or vitamins disclosed by their GP indicated that less
than 80% were issued in the previous 12 months using
the MRA method described above.Beliefs about medicines questionnaire-specific (BMQ)
The BMQ-specific is a self-report questionnaire with
separate versions for parents and children (≥11 years)
to quantify beliefs in terms of necessity and concerns
about treatment. Refined versions were administered
separately for enzyme supplements, vitamins and chest
physiotherapy. This scale has previously been adminis-
tered to adolescents with cystic fibrosis where the need
for further development of the concern scale for chest
physiotherapy was recommended [10]. As such, three
items were added to the concerns scale for chest
physiotherapy “I/My child finds chest physiotherapy
tiring”, “I/My child finds it embarrassing to carry out
chest physiotherapy” and “Chest physiotherapy makes
me/my child feel worse”. One additional item was in-
cluded for all therapies, “This treatment gives me/my
child unpleasant side effects”. These modifications were
made during the study design phase in consultation
with the author of the BMQ-specific and successfully
piloted in 10 parents and their children (≥11 years)
with no further amendments requested.
Due to the different numbers of questions depending
on which therapy was being explored using the BMQ,
the necessity and concern scores were summed for each
participant and transformed to range from 0-100. High
scores on each subscale indicated high necessity or con-
cern beliefs respectively. The internal reliability, of the
necessity and concern scales of the BMQ-specific for
parents and children ≥11 years ranged from (0.75-0.90).
Center for epidemiologic studies depression scale (CES-D)
The CES-D is a short 20-item validated scale to measure
depressive symptoms in the general population [23]. In
the present study the CES-D was administered to parents.
A cut-off score of ≥16 was used to establish whether
parents were experiencing clinically relevant depressive
symptoms [23]. The CES-D, in preference to the Hospital
Anxiety and Depression Scale, was chosen to prevent
underestimation of depressive symptoms present in parents
of children with cystic fibrosis [24].
The order of questionnaire administration remained
consistent throughout the study (BMQ, MARS, CES-D).
Researchers administering questionnaires were independentof the clinicians and this was stressed to reduce any
perceived pressure of social desirability.
Data analysis
All analyses were conducted using IBM SPSS Statistics
(version 19, SPSS Inc, USA). Group differences (high-
adherers and low-adherers) were examined using t-tests
or the Mann Whitney U test, as appropriate for continuous
variables, e.g. beliefs about medicines. Group differences for
categorical variables were examined using Chi-square
analysis or the Fisher’s Exact test, as appropriate. The
significance level was set at 0.05 throughout.
Due to the large number of variables investigated and
comparatively low number of high-adherence observa-
tions, only those factors which were shown to have
significant influences on adherence or had a p value of
p < 0.2 were subjected to multivariate analysis using
logistic regression. Separate analyses were conducted for
adherence to enzyme supplements (n = 80), vitamins
(n = 88) and chest physiotherapy (n = 98).
The validity of the refined MARS and BMQ-specific
were assessed using Principal Component Analysis on
IBM SPSS Statistics (version 19, SPSS Inc, USA). Internal
reliability of all questionnaires was quantified using
Cronbach’s alpha, for each dimension.
Results
A total of 100 participants were enrolled during the study
(Figure 1). The baseline characteristics of participants are
shown in Table 1. Children who did not participate in the
study did not differ significantly in terms of age, gender,
BMI percentile or P.aeruginosa colonisation status. Non-
participants did, however, have significantly higher FEV1%
predicted when compared to participants (p < 0.01). The
majority of parents recruited to the study were mothers
(83%). Enzyme supplements were prescribed for 81 children,
vitamins were prescribed for 98 children and chest physio-
therapy was prescribed for 99 children.
Adherence to treatment varied depending on the
adherence measurement method used, treatment type
and respondent (i.e. parent or child) (Figure 2). Using
the composite adherence measurement approach 58
(72%) were classified as low-adherers to enzyme
supplements, 58 children (59%) were classified as low-
adherers to vitamins and 48 (49%) were classified as
low-adherers to chest physiotherapy (Figure 2). Seventy
nine participants were prescribed all three treatments,
the number of participants classified as high adherers
to all treatments was 14, whereas, 25 were classified as
low adherers to all treatments. Children ≥11 years were
Total population
n=182
Recruited
n=100
Declined
n=30
Not interested
n= 18
Too busy/no time 
n=12
Not approached
n=52
Due to transfer, clinic non-attendance, 
recruitment limit reached
n=46
Recent death in the family
n=1
Not competent to give assent 
n=1
Not accompanied by parent/guardian
n=4
Figure 1 Participant enrolment.
Goodfellow et al. BMC Pulmonary Medicine  (2015) 15:43 Page 5 of 10significantly more likely to report low-adherence to en-
zyme supplements than their parents (p < 0.01).
Beliefs about treatments varied across treatments and
respondents. Concern beliefs about treatment were low
for all three treatments, particularly vitamins. Parents
and children reported high necessity beliefs for enzyme
supplements and chest physiotherapy. Necessity beliefs
for vitamins were lower by comparison. In a subgroup of
children 11-18 years and their parents (who both com-
pleted the BMQ) it was revealed that there were signifi-
cant differences in the strength of necessity beliefs with
parents having significantly stronger necessity beliefs for
enzyme supplements (n = 66; p = 0.03), vitamins (n = 86;
p < 0.01) and chest physiotherapy (n = 86; p < 0.01) than
their children. Similarly, parents were shown to have
higher concerns about chest physiotherapy than their chil-
dren (n = 86; p = 0.04) (Figure 3).
Clinically relevant depressive symptoms present in par-
ents, as measured by the CES-D, occurred in 21 parents
(23.3%). Approximately half of these parents (n = 10)
reported scores ≥27 which can be indicative of major de-
pression [25]. There were missing data for 5 parents and
5 parents declined to complete this questionnaire.
Full details of the univariate analysis for each treatment
are presented in an Additional file 1. A summary of fac-
tors showing significance or those which had a p value of
p < 0.2 are presented in Table 2.A preliminary effects model was constructed using those
variables that had a p value of p < 0.20 in the univariate
analysis. The preliminary effects model for enzyme supple-
ments included; increasing age, increasing parental BMQ
necessity score and increasing parental BMQ concern
score. The preliminary effects model for vitamins in-
cluded; increasing age, presence of concurrent medical
condition, increasing parental BMQ concern score, in-
creasing CES-D score. The preliminary effects model for
chest physiotherapy included; increasing age, number of
medications, presence of concurrent medical condition,
increasing parental BMQ necessity score and increasing
parental BMQ concern score. Bacterial colonisation status
and child scores on the BMQ were not included in the
logistic regression analyses as the low number in the high-
adherence group precluded analysis. A backward stepwise
logistic regression analysis was then performed on the pre-
liminary effects models. The resulting main effects models
for enzyme supplements and chest physiotherapy are
presented in Tables 3 and 4. No main effects model is pre-
sented for vitamins as none of the variables accounted for
an independent statistically significant contribution to
predicting adherence to vitamins. Based on these models,
child age and parental necessity beliefs were predictive of
adherence to enzyme supplements and chest physiotherapy.
Advancing age in children, was associated with a decreased
likelihood of adherence to enzyme supplements (OR = 0.79,
Table 1 Baseline characteristics of participants
Child characteristics Participants
Age of child (years) n = 100
Median (range) 10.1 (0.2-18.6)
Gender n = 100
% male 44
Ethnicity n = 100
% Caucasian 100
FEV1% predicted (in children over 6 years) n = 71
FEV1 ≥ 70% (mild disease) 57 (80.3%)
FEV1 40-69% (moderate disease) 11 (15.5%)
FEV1 ≤ 39% (severe disease) 3 (4.2%)
Mean FEV1% predicted (±95% C.I.) 84% (±4.54)
BMI percentile (children <18 years) n = 98
<15th percentile 10 (10.2%)
≥15th percentile 88 (89.8%)
BMI (≥18 years) n = 2
≥18.5 ≤ 25 2 (100%)
Swachman-Kulczycki radiological score/25
Median (IQR) 22 (20-23)
Colonisation status n = 100
B.cepacia 5 (5% chronic)
Methicillin-resistant Staphylococcus aureus (MRSA) 7 (7% chronic)
P.aeruginosa† 3 (3% intermittent)
12 (12% chronic)
Days in hospital over the previous year n = 100
Median (IQR) 0 (0-1.75)
Number of medications currently prescribed n = 100
Median (IQR) 6 (4-8)
Enzyme supplement prescribed [n = %] 81 (81%)
Vitamins prescribed [n = %] 98 (98%)
Chest physiotherapy prescribed [n = %] 99 (99%)
Other medical diagnosis
No 84 (84%)
Yes 16 (16%)
†P.aeruginosa classified as chronic using the Leeds criteria. FEV1 forced
expiratory volume in 1 s; BMI body mass index; IQR inter-quartile range.
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whereas, increased parental necessity beliefs was associated
with improved adherence to these therapies (OR = 1.05
each). Parental depressive symptoms were not found to be
predictive of adherence to enzyme supplements, vitamins
or chest physiotherapy in the population studied.
Discussion
In the current study 55% children (≥11 years) and 92%
parents indicated high-adherence to enzyme supple-
ments using self-report methods. This contrasts withprevious studies in children using self-report which
indicated that adherence to enzyme supplements lies
between 77-98% [3,26,27]. Overall only 28% of partici-
pants were classified as high-adherers when all methods
(including prescription refill and prescription issue
data) were taken into account. This rate of adherence is
comparable to diary data (27%) observed in studies in
the USA [3]. With regards to vitamins, self-reported ad-
herence was high (90% parents; 81% children ≥11 years)
and similar to the range illustrated by previous studies
using self-report measures [3]. Using the multi-method
approach described, 41% of children were classified as
high-adherers to vitamins which is comparable to the
proportion of children classified as adherent in a US
study investigating pharmacy refill adherence and diary
data (34% and 22% respectively) [3]. To assess adherence to
chest physiotherapy only parent and child self-reports were
assessed as there were no objective measures available.
Nevertheless, 51% of children (≥11 years) and 61% parents
reported adherence to chest physiotherapy which fell within
the expected range for this method of measurement [3,27].
In order to reduce bias from one particular adherence
measurement method, a multi-method approach was
employed to assess adherence in the current study.
Previously, overestimation of adherence by 25.3% to
nebulised therapy using self-report was reported when
compared to electronic monitoring [28]. Overestimation
of adherence using self-report was also evidenced in the
present study in comparison to prescription data ob-
tained for enzyme supplements and vitamins. When
children (≥11 years) used the self-report measure, their
responses were closer to non-adherence measured via
the objective pharmacy and GP prescription data when
compared with their parents. This difference has not pre-
viously been reported in the literature and this could
occur because parents are more aware of socially desirable
responses or that parents believe that their children are
taking their medication when in fact they are not.
This is the first study to investigate the influence of
parental beliefs and depressive symptoms on child
adherence to therapy in cystic fibrosis. Parental beliefs
about the necessity of enzyme supplements and chest
physiotherapy were found to be predictive of their child’s
adherence to these therapies. For every percentage
increase in score children were 5% more likely to be ad-
herent to enzyme supplements and chest physiotherapy.
Children whose parents had reported high necessity
beliefs regarding their child’s use of enzyme supplements
or chest physiotherapy were significantly more likely to
be classified as high-adherers to these treatments. It has
been reported previously that poor adherence to nebulised
therapy in adults was associated with doubts about nebu-
liser necessity and similarly, non-adherence to antibiotics
and chest physiotherapy has been related to adolescents’
MARS Medication Adherence Report Scale; MRA Medication Refill Adherence
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Figure 2 Classification of low-adherence using a multi-method approach.
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the present study, necessity beliefs for all treatments
were significantly higher for parents of children 11-18
years than those reported by their children. One reason
for this may be that children have inconsistent treat-
ment goals compared to those of parents and physicians
[29]. The finding that children may perceive necessity of
treatment differently to their parents could be of par-
ticular importance when children become autonomous
and have more responsibility for their treatments.
The finding that vitamins received lower necessity and
concern scores compared with enzyme supplements and
chest physiotherapy indicates a lack of understanding
surrounding the importance of vitamin supplementation
in children with cystic fibrosis. Vitamins are perhaps not0
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Figure 3 Graph illustrating beliefs about treatments in a subset of childrenconsidered ‘real’ medicines by parents and children since
they are widely available without prescription. This could
explain why parental beliefs about vitamins were not
predictive of their child’s adherence to this treatment.
Concern beliefs were not significant independent predic-
tors of treatment adherence, however, this could have
been due to the low levels of concern expressed about
the treatments in this sample.
In the present study approximately a quarter (23.3%)
of parents reported symptoms indicative of depression.
This corresponds to data reported from the UK arm of
the TIDES-CF study which indicated that 28.3% of
parents reported clinically relevant levels of depressive
symptoms [30]. Additionally, caregiver rates of depression
have been found to vary significantly between maternal andst physiotherapy
Parent necessity (of child 
Parent concern (of child 
*
*
(≥11 years) and their parents.
Table 2 Summary of group differences (for variables with p < 0.2) between high adherers and low adherers
Treatment Parameter High- adherers Low-adherers p
Enzyme supplements Age n = 23 n = 58
Median (IQR) 6 (2-10) 11.5 (7.5-15) ≤0.001*
Colonisation status
n (%)
P.aeruginosa
Chronic (n = 11) 0 (0) 11 (19)
Not chronic (n = 70) 23 (100) 47 (81) 0.029*
BMQ (parent) n = 23 n = 58
median (IQR)
Necessity 85 (80-100) 80 (65-96) 0.129§
Concern 21 (13-38) 29 (17-42) 0.073§
BMQ (child) n = 2 n = 31
median (IQR)
Concern 6 (N/A) 21 (13-33) 0.120§
Vitamins Age n = 40 n = 58 0.074§
Median (IQR) 9 (3-12) 12 (6-15)
Colonisation status
n (%)
P.aeruginosa
Chronic (n = 12) 2 (5) 10 (17)
Not chronic (n = 1) 38 (95) 48 (83) 0.115§
Presence of concurrent medical condition
n (%)
Yes (n = 15) 9 (23) 6 (10)
No (n = 83) 31 (78) 52 (90) 0.175§
BMQ (parent) n = 40 n = 58
median (IQR)
Concern 17 (4-25) 21 (8-33) 0.117§
CES-D (parent) n = 37 n = 51
Median (IQR) 6 (3-14) 11 (5-15) 0.073§
Chest physiotherapy Age n = 50 n = 48 ≤0.001*
Median (IQR) 7 (2-11) 13 (8-15)
Number of medications currently prescribed n = 50 n = 48
Median (IQR) 6 (5-8) 5 (4-8) 0.080§
Presence of concurrent medical condition
n (%)
Yes (n = 16) 4 (8) 12 (25)
No (n = 82) 46 (92) 36 (75) 0.045*
BMQ (parent) n = 50 n = 48
median (IQR)
Necessity 95 (85-100) 80 (70-95) 0.001*
Concern 25 (22-33) 33 (23-47) 0.032*
§p < 0.2; *p < 0.05; IQR inter-quartile range; BMQ Beliefs about Medicines Questionnaire; CES-D Centre for Epidemiologic Studies Depression Scale.
Full results available in Additional file 1.
Goodfellow et al. BMC Pulmonary Medicine  (2015) 15:43 Page 8 of 10
Table 3 Main effects model for high adherence to
enzyme supplements
Independent variable B SE Odds ratio (OR) 95% CI of OR
Increasing age (in years) -0.23 0.06 0.79* 0.70-0.90
Increasing parental
BMQ necessity score
0.05 0.02 1.05* 1.01-1.09
B regression coefficient; SE standard error associated with the coefficient B;
*p < 0.05; n = 80 (1 case removed due to outlier); BMQ Beliefs about Medicines
Questionnaire. The model explained between 23.9% (Cox and Snell R Square)
and 34.5% (Nagelkerke R square) of the variance in adherence status.
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significantly more depressive symptoms, i.e. 35% com-
pared with 25% [14]. In this study parental depressive
symptoms were not found to be independently predictive
of child adherence to enzyme supplements, vitamins or
chest physiotherapy, therefore, no evidence was found
to support the use of routine monitoring of parental
depressive symptoms as an indicator for poor treatment
adherence in their children within the present study
population. This contrasts with previous reports indi-
cating parental depressive symptoms were associated
with enzyme supplement and chest physiotherapy ad-
herence in children [15-18].
Child age was also an important adherence indicator;
for each advancing year, adherence to enzyme supple-
ments and chest physiotherapy was reduced by approxi-
mately 20%. This observation that advancing age reduces
adherence to therapy in cystic fibrosis supports previous
European findings [27]. Barriers to treatment adherence
specifically reported by adolescents include time pressures,
competing priorities, privacy concerns and lack of conse-
quences of treatment non-adherence [11].
Limitations
When monitoring adherence to treatment, each measure-
ment method has integral limitations, however, this was
minimised by adopting a multi-method approach to
measurement. Additionally, due to the nature of cross-
sectional study design, causality could not be deter-
mined. Insufficient sample size precluded analysis of
bacterial colonisation and BMQ child responses between
adherent and non-adherent groups. Pharmacy recordsTable 4 Main effects model for high adherence to chest
physiotherapy
Independent variable B SE Odds ratio 95% CI
Increasing age (in years) -0.20 0.05 0.82* 0.74-0.90
Increasing parental BMQ
necessity score
0.05 0.02 1.05* 1.02-1.09
B regression coefficient; SE standard error associated with the coefficient B;
*p < 0.05; *p < 0.01; n = 98 (1 case had missing data); BMQ Beliefs about
Medicines Questionnaire. The model explained between 27.1% (Cox and
Snell R square) and 36.2% (Nagelkerke R square) of the variance in
adherence status.are not a closed system, however, all pharmacies identi-
fied by parents were contacted and patient medication
records received. There was the potential for selection
bias to occur with those who did not participate poten-
tially being less adherent to treatment, therefore the
adherence levels reported in this article should be
regarded as conservative estimates.
Conclusions
Low adherence to enzyme supplements, vitamins and
chest physiotherapy was revealed. Future research
should focus on why there is a significant difference
between parent and child beliefs about treatments and
on the process of parental transfer of beliefs about
treatment. Future adherence interventions addressing
parental beliefs about enzyme supplements and chest
physiotherapy may improve child adherence to treat-
ment. There is a larger scope to improve adherence if
interventions are targeted at older children.
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